Genmab — Januar 2013
-
The purpose of this study is to determine whether we could improve the CR rate of the golden standard treatment for fit patients with CLL , the FCR regimen, with a chemoimmunotherapy including FC combined with an increased dose of the monoclonal antibody ofatumumab
-
-
det er jo så direkte op imod
-
rityx
-
ritux
-
som er the golden standard treatment i dag
-
vi er nu oppe på 92
-
ikke i kurs men i forsøg
-
-
den vil nok stige på news. Men den er allerede steget 10-15% i år, så det er et af de svære spørgsmål. Jeg ved det ikke. Men den kommer til at rykke på nyheder. Næste nyhed salgstal 6. februar 1300
-
nu med rumklang https://www.youtube.com/watch?v=0f-dLKFWH-g
-
OC vs C fase III står nu som rekrutterende igen. Mærkeligt! http://www.clinicaltrials.gov/ct2/show/NCT00748189?term=ofatumumab&phase=2&rank=6&submit_fld_opt=
-
Den stør som rekrutterende i Indien, Italien og Moskva???
-
står
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind